Youth-onset type 2 diabetes in Israel: A national cohort.
children and adolescents
ethnicity
metabolic syndrome
obesity
youth-onset type 2 diabetes
Journal
Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
23
03
2022
received:
22
11
2021
accepted:
21
04
2022
pubmed:
7
5
2022
medline:
10
8
2022
entrez:
6
5
2022
Statut:
ppublish
Résumé
Prevalence of youth-onset type 2 diabetes (T2D) has increased worldwide, paralleling the rise in pediatric obesity. Occurrence and clinical manifestations vary regionally and demographically. We assessed the incidence, and clinical and demographic manifestations of youth-onset T2D in Israel. In a national observational study, demographic, clinical, and laboratory data were collected from the medical records of children and adolescents, aged 10-18 years, diagnosed with T2D between the years 2008 and 2019. The incidence of youth-onset T2D in Israel increased significantly from 0.63/100,000 in 2008 to 3.41/100,000 in 2019. The study cohort comprised 379 individuals (228 girls [59.7%], 221 Jews [58.3%], mean age 14.7 ± 1.9 years); 73.1% had a positive family history of T2D. Mean body mass index (BMI) z-score was 1.96 ± 0.7, higher in Jews than Arabs. High systolic (≥ 130 mmHg) and diastolic blood pressure (≥ 85 mmHg) were observed in 33.7% and 7.8% of patients, respectively; mean glycosylated hemoglobin (A1c) level at diagnosis was 8.8 ± 2.5%. Dyslipidemia, with high triglyceride (>150 mg/dl) and low HDL-c (<40 mg/dl) levels, was found in 45.6% and 56.5%, respectively. Microalbuminuria and retinopathy were documented at diagnosis, 15.2% and 1.9%, respectively) and increased (36.7% and 4.6%, respectively) at follow-up of 2.9 ± 2.1 years. Criteria of metabolic syndrome were met by 224 (62.2%) patients, and fatty liver documented in 65%, mainly Jews. Psychosocial comorbidity was found in 31%. Treatment with metformin (45.6%), insulin (20.6%), and lifestyle modification (18%) improved glycemic control. Youth-onset T2D in Israel has increased significantly and presents a unique profile.
Sections du résumé
BACKGROUND
Prevalence of youth-onset type 2 diabetes (T2D) has increased worldwide, paralleling the rise in pediatric obesity. Occurrence and clinical manifestations vary regionally and demographically.
OBJECTIVES
We assessed the incidence, and clinical and demographic manifestations of youth-onset T2D in Israel.
METHODS
In a national observational study, demographic, clinical, and laboratory data were collected from the medical records of children and adolescents, aged 10-18 years, diagnosed with T2D between the years 2008 and 2019.
RESULTS
The incidence of youth-onset T2D in Israel increased significantly from 0.63/100,000 in 2008 to 3.41/100,000 in 2019. The study cohort comprised 379 individuals (228 girls [59.7%], 221 Jews [58.3%], mean age 14.7 ± 1.9 years); 73.1% had a positive family history of T2D. Mean body mass index (BMI) z-score was 1.96 ± 0.7, higher in Jews than Arabs. High systolic (≥ 130 mmHg) and diastolic blood pressure (≥ 85 mmHg) were observed in 33.7% and 7.8% of patients, respectively; mean glycosylated hemoglobin (A1c) level at diagnosis was 8.8 ± 2.5%. Dyslipidemia, with high triglyceride (>150 mg/dl) and low HDL-c (<40 mg/dl) levels, was found in 45.6% and 56.5%, respectively. Microalbuminuria and retinopathy were documented at diagnosis, 15.2% and 1.9%, respectively) and increased (36.7% and 4.6%, respectively) at follow-up of 2.9 ± 2.1 years. Criteria of metabolic syndrome were met by 224 (62.2%) patients, and fatty liver documented in 65%, mainly Jews. Psychosocial comorbidity was found in 31%. Treatment with metformin (45.6%), insulin (20.6%), and lifestyle modification (18%) improved glycemic control.
CONCLUSION
Youth-onset T2D in Israel has increased significantly and presents a unique profile.
Substances chimiques
Glycated Hemoglobin A
0
Metformin
9100L32L2N
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
649-659Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Federation ID. IDF Diabetes Atlas. ninth ed. International Diabetes Federation; 2019 Retrieved October 10, 2021, from https://www.diabetesatlas.org/en/
Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr. 1996;128(5 I):608-615.
Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Type 2 diabetes in the young: the evolving epidemic. The international diabetes Federation consensus workshop. Diabetes Care. 2004;27(7):1798-1811.
Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311(17):1778-1786.
Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med. 2017;376(15):1419-1429.
Divers J, Mayer-Davis EJ, Lawrence JM, et al. Trends in incidence of type 1 and type 2 diabetes among youths - selected counties and Indian reservations, United States, 2002-2015. MMWR Morb Mortal Wkly Rep. 2020;69(6):161-165.
Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trendsinobesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016. JAMA. 2018;319(16):1723-1725.
Liu LL, Lawrence JM, Davis C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for diabetes in youth study. Pediatr Diabetes. 2010;11(1):4-11.
Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146(5):693-700.
Fazeli Farsani S, Van Der Aa MP, Van Der Vorst MMJ, Knibbe CAJ, De Boer A. Global trends in the incidence and prevalence of type 2 diabetes in children and adolescents: a systematic review and evaluation of methodological approaches. Diabetologia. 2013;56(7):1471-1488.
TODAY Study Group, Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366(24):2247-2256.
Viner R, White B, Christie D. Type 2 diabetes in adolescents: a severe phenotype posing major clinical challenges and public health burden. Lancet. 2017;389(10085):2252-2260.
Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among north American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr. 2000;136(5):664-672.
Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96(1):159-167.
Klingensmith GJ, Connor CG, Ruedy KJ, et al. Presentation of youth with type 2 diabetes in the pediatric diabetes consortium. Pediatr Diabetes. 2016;17(4):266-273.
Chernausek SD, Arslanian S, Caprio S, et al. Relationship between parental diabetes and presentation of metabolic and glycemic function in youth with type 2 diabetes: baseline findings from the TODAY trial. Diabetes Care. 2016;39(1):110-117.
Cheng TS, Day FR, Lakshman R, Ong KK. Association of puberty timing with type 2 diabetes: a systematic review and meta-analysis. PLoS Med. 2020;17(1):e1003017.
Weiss R, Caprio S, Trombetta M, Taksali SE, Tamborlane WV, Bonadonna R. β-Cell function across the spectrum of glucose tolerance in obese youth. Diabetes. 2005;54(6):1735-1743.
Elder DA, Hornung LN, Herbers PM, Prigeon R, Woo JG, D'Alessio DA. Rapid deterioration of insulin secretion in obese adolescents preceding the onset of type 2 diabetes. J Pediatr. 2015;166(3):672-678.
Dart AB, Martens PJ, Rigatto C, Brownell MD, Dean HJ, Sellers EA. Earlier onset of complications in youth with type 2 diabetes. Diabetes Care. 2014;37(2):436-443.
Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of Type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA. 2017;317(8):825-835.
TODAY Study Group, Bjornstad P, Drews KL, Caprio S, et al. Long-term complications in youth-onset type 2 diabetes. N Engl J Med. 2021;385(5):416-426.
Rodriguez BL, Fujimoto WY, Mayer-Davis EJ, et al. Prevalence of cardiovascular disease risk factors in U.S. children and adolescents with diabetes: the SEARCH for diabetes in youth study. Diabetes Care. 2006;29(8):1891-1896.
Weinstock RS, Drews KL, Caprio S, Leibel NI, Mckay SV, Zeitler PS. Metabolic syndrome is common and persistent in youth-onset type 2 diabetes: results from the TODAY clinical trial. Obesity. 2015;23:1357-1361.
Meyerovitch J, Zlotnik M, Yackobovitch-Gavan M, Phillip M, Shalitin S. Real-life glycemic control in children with type 2 diabetes: a population-based study. J Pediatr. 2017;188:173-180.e1.
Central Bureau of Statistics The state of Israel. Statistical abstract of Israel 2020. Stat Abstr Isr. 2020;71. Retrived October 10, 2021 from: https://www.cbs.gov.il/publications/statistical-abstract-of-Israel-2020/Tables-2.1-2.3
American Diabetes Association. Children and adolescents: standards of medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S126-S136.
Zeitler P, Arslanian S, Fu J, et al. ISPAD clinical practice consensus guidelines 2018: type 2 diabetes mellitus in youth. Pediatr Diabetes. 2018;19:28-46.
Zimmet P, Alberti GKMM, Kaufman F, et al. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes. 2007;8(5):299-306.
Tropeano A, Corica D, Pomi AL, et al. The metabolic syndrome in pediatrics: do we have a reliable definition? A systematic review. Eur J Endocrinol. 2021;185(2):265-278.
Di Bonito P, Moio N, Scilla C, et al. Usefulness of the high triglyceride-to-HDL cholesterol ratio to identify cardiometabolic risk factors and preclinical signs of organ damage in outpatient children. Diabetes Care. 2012;35(1):158-162.
Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nu. J Pediatr Gastroenterol Nutr. 2017;64(2):319-334.
Ibáñez L, Oberfield SE, Witchel S, et al. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr. 2017;88(6):371-395.
Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019;381(7):637-646.
Van Name MA, Cheng P, Gal RL, et al. Children and adolescents with type 1 and type 2 diabetes mellitus in the pediatric diabetes consortium registries: comparing clinical characteristics and glycaemic control. Diabet Med. 2020;37(5):863-867.
Lawrence JM, Divers J, Isom S, et al. Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017. JAMA. 2021;326(8):717-727.
Kalter-Leibovici O, Chetrit A, Lubin F, et al. Adult-onset diabetes among Arabs and Jews in Israel: a population-based study. Diabet Med. 2012;29:748-754.
Jaffe A, Giveon S, Wulffhart L, et al. Adult Arabs have higher risk for diabetes mellitus than Jews in Israel. PLoS One. 2017;12(5):e0176661.
Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129-2140.
Hockett CW, Praveen PA, Ong TC, et al. Clinical profile at diagnosis with youth-onset type 1 and type 2 diabetes in two pediatric diabetes registries: SEARCH (United States) and YDR (India). Pediatr Diabetes. 2021;22(1):22-30.
Twig G, Zucker I, Afek A, et al. Adolescent obesity and early-onset type 2 diabetes. Diabetes Care. 2020;43(7):1487-1495.
Gabbay U, Carmi D, Mimouni-Bloch A, El Goldstein B, Keinan-Boker L, Meyerovitch J. Do Israeli children's anthropometrics comply with world health organization and U.S. centers for disease control and prevention height and body mass index tables? Isr Med Assoc J. 2021;23(4):233-238.
Todd JN, Srinivasan S, Pollin TI. Advances in the genetics of youth-onset type 2 diabetes. Curr Diab Rep. 2018;18(8):57.
Nadeau KJ, Klingensmith G, Zeitler P. Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase. J Pediatr Gastroenterol Nutr. 2005;41(1):94-98.
Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American diabetes association. Diabetes Care. 2018;41(12):2648-2668.
Tryggestad JB, Willi SM. Complications and comorbidities of T2DM in adolescents: findings from the TODAY clinical trial. J Diabetes Complicat. 2015;29(2):307-312.
Levitt Katz LE, Swami S, Abraham M, et al. Neuropsychiatric disorders at the presentation of type 2 diabetes mellitus in children. Pediatr Diabetes. 2005;6(2):84-89.
Amutha A, Praveen PA, Hockett CW, et al. Treatment regimens and glycosylated hemoglobin levels in youth with type 1 and type 2 diabetes: data from SEARCH (United States) and YDR (India) registries. Pediatr Diabetes. 2021;22(1):31-39.
Yang Y, Chan L. Monogenic diabetes: what it teaches us on the common forms of type 1 and type 2 diabetes. Endocr Rev. 2016;37(3):190-222.
Kleinberger JW, Copeland KC, Gandica RG, et al. Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet Med. 2018;20(6):583-590.
Carlsson A, Shepherd M, Ellard S, et al. Absence of islet autoantibodies and modestly raised glucose values at diabetes diagnosis should Lead to testing for MODY: lessons from a 5-year pediatric Swedish National Cohort Study. Diabetes Care. 2020;43(1):82-89.
Zhang H, Colclough K, Gloyn AL, et al. Monogenic diabetes: a gateway to precision medicine in diabetes. J Clin Invest. 2021;131(3):e142244.
Todd JN, Kleinberger JW, Zhang H, et al. Monogenic diabetes in youth with presumed type 2 diabetes: results from the Progress in diabetes genetics in youth (ProDiGY) collaboration. Diabetes Care. 2021;44(10):2312-2319.
Shehadeh N, Bakri D, Njølstad PR, et al. Clinical characteristics of mutation carriers in a large family with glucokinase diabetes (MODY2). Diabet Med. 2005;22(8):994-998.
Elias-Assad G, Saab R, Molnes J, et al. Maturity onset diabetes of the young type 2 (MODY2): insight from an extended family. Diabetes Res Clin Pract. 2021;175:108791.